MEAK
99 years and younger
All genders
Primary: to evaluate the safety and tolerability of single doses of AUT00201 in patients with MEAK. Secondary: -To characterize the correlation of exposure to AUT00201 with effects on measures of cortical inhibition, as assessed by paired-pulse transcranial magnetic stimulation (TMS), in patients with MEAK -To assess the pharmacokinetic (PK) profile …